BeiGene Ltd/ US07725L1026 /
2024-05-08 9:59:46 PM | Chg. +3.49 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
164.27USD | +2.17% | 20,843 Turnover: 3.43 mill. |
-Bid Size: - | -Ask Size: - | 167.90 | 161.74 |
GlobeNewswire
05-02
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-02
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business...
GlobeNewswire
04-11
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
GlobeNewswire
03-28
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
03-05
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the ...
GlobeNewswire
02-27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire
02-27
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights ...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
01-08
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the ...
GlobeNewswire
2023-11-07
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
GlobeNewswire
2023-11-07
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disea...
GlobeNewswire
2023-11-02
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights